Neurological Diseases and Pathophysiology of Cytokine Storm in Coronavirus disease

Md Moshiur Rahman*[1], Ruma parvin[2], A.H.M Khairul Bashar[3], Mohammad Noor A Alam[4], K.M. Ziaur Rahman[5], AQM Omar Sharif[6] and Mohammad Shahidullah[7]

[1]*Neurosurgery Department, Holy Family Red Crescent Medical College, Dhaka*

[2]*Associate professor, DR.M R Khan Shishu Hospital & Institute of Child Health, Dhaka.*

[3]*Assistant professor, Sylhet MAG Osmani Medical College, Dhaka.*

[4]*Professor, Department of Surgery, BIRDEM and Ibrahim Medical College, Dhaka.*

[5]*Senior resident, Neurosurgery Department, Holy Family Red Crescent Medical College, Dhaka.*

[6]*Consultant, Ophthalmologist, Shahid Suhrawardy Medical College & Hospital, Dhaka.*

[7]*Department of Neurology, Holy Family Red Crescent Medical College, Dhaka.*

Corresponding Author*

Md Moshiur Rahman, Assistant professor, Neurosurgery Department, Holy Family Red Crescent Medical College, Dhaka, Email: dr.tutul@yahoo.com

Received date: 11 Sep 2020; **Accepted date:** 13 Sep 2020; **Published date:** 28 Sep 2020

Introduction

Cytokine storm is a term that is applied to response to pathogens causing cytokine discharge. The pathogenesis is mind-boggling however incorporates loss of administrative control of pro-inflammatory cytokine creation, both at nearby and fundamental levels. The infection advances quickly, and the mortality is high. Cytokine storm is considered as one of the significant reasons for acute respiratory distress syndrome (ARDS) and different organ failure.1,2 Some proof shows that, during the coronavirus infection 2019 (COVID-19) period, serious crumbling in certain patients has been firmly connected with dysregulated and over the top cytokine discharge. In this manner, successfully stifling the cytokine storm is a significant method to forestall the crumbling of patients with COVID-19 disease.3 The COVID-19 pandemic has changed the demonstration of medicine and neurosurgery around the world, as requirements across clinical systems move to oblige a flood in COVID-19 patients. This discussion denotes that we are aware of the pathogenesis and treatment modalities of the COVID-19 infection as well as neurological diseases associated with it, to give some foundation to illuminate future direction for clinical treatment.

In some patients, the immune system activation against COVID-19 is massive and creates a hyperactive immune response called cytokine storm.4 This is applicable to understanding the current COVID-19 flare-up, specifically as it has been accounted for that people who have been freed from COVID-19 contamination. Increase level of pro-inflammatory cytokines & chemokines are present in COVID-19, SARS, and MERS-CoV infection.5 These are mainly IL-1B, IL-6, IL-12, Interferon γ, CXCL 10, CCL 2. Additionally in COVID-19, there are IL-4, IL-10 that can cause immune suppression.6 In COVID-19 patients CD4, CD8, NK T cells are low and monocyte & macrophages are high, which is the explanation of increase levels of these chemicals.7 These chemicals cause abnormal inflammation to lung and other organs of the body creating ARDS & multi-organ failure.7 ARDS may cause significant mortality in COVID-19 patients and considered as the hallmark of immune system-related pathology in this virus infection.8 This usually occurs in the elderly and patients having other comorbidities. High ferritin, CRP, D-Dimer, LDH, hepatic dysfunction are the biomarkers for this syndrome. This storm, can cause thrombosis and/or DIC, carries a high risk for the patient.9 The account proof of inordinate cytokine enactments in patients in the wake of fruitful disposal of spreading infections, for example, COVID-19, could be educational for foreseeing future instances of certain neurological illnesses. Numerous COVID-19 patients present symptoms in the viral illness with lost smell, which is a neurological sign. Loss of smell is a notable antecedent signal for building up many neurodegenerative diseases.

Diagnosis and management of cytokine storms are clinically testing and dubious because of the absence of demonstrated treatment. The cytokine storm instigated by irresistible infections is the aftereffect of an auto amplifying marvel expecting to crush the invader and re-establish homeostasis that will inevitably prompt sepsis. While the comprehension of the organization of the cytokine-instigated cell reaction during sepsis is in steady advancement, we despite everything come up short on a worldwide integrative view, in reality. The association of the host reaction to contamination, locally and distantly, is still not completely understood. Despite the identity of key particles, for example, the significant tumor putrefaction factor-alpha, each endeavor meaning to hose this cytokine storm actuation or outcomes fizzled in clinical preliminaries. While the specific triggers or connectors that ought to be focused on are still to be recognized, the endothelium as a hub of insusceptible reaction gives off an impression of being a substantial and promising objective. The following decade will presumably observe a more exact delineation of in-cell, in-organ, and worldwide reaction to disease; there is no uncertainty that future disclosures will challenge our air conditioning dual ideas and will cause us to return to our helpful focuses on; this makes the battle against this emotional reaction to contamination an energizing test. The neuroinvasive capability of COVID-19 and the relationship among neuroinvasion and cytokine storm need further thought.10-12 A large number of the neurological impacts of COVID-19 might act naturally restricting, and resolve with no stamped harm to the cerebrum and fringe sensory system. A few doctors may encourage patients to utilize calming drugs or decide the specific cytokine-to tolerant profiles that speak to high hazard for neurodegenerative diseases, and have the option to suggest medicines in the post-viral recuperation stage in the serious COVID-19 patients. Finding the particular cytokines that cause to

post-viral fundamental and neighborhood aggravation that prompts genuine malady in people may permit mediations to forestall genuine neurological ailment results. Understanding the different pathophysiological instruments connected to cytokine tempest could be utilized to focus on indicative and remedial systems for COVID-19 patients.

References

1. B.G. Chousterman, F.K. Swirski, G.F. WeberCytokine storm and sepsis disease pathogenesis Seminars Immunopathol, 39 (5) (2017), pp. 517-528.
2. A.ShimabukuroVornhagen, P. Gödel, M. Subklewe, H.J. Stemmler, H.A. Schlößer, M. Schlaak, etal. Cytokine release syndrome J Immuno Therapy Cancer, 6 (1) (2018), p. 56.
3. Wan S., Yi Q., Fan S., Lv J., Zhang X., Guo L., et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). 2020:medRxiv2020.02.10.20021832.
5. C. Huang, Y. W. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395 (10223), 497-506.
6. C. Zhang, Z. W. (2020). The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents, Article 105954.
8. F Coperchini, L. C. (2020). The cytokine storm in COVID-19: An overview of the involvement of the. Cytokine and Growth Factor Reviews, 53, 25-32.
9. M Soy, G. K. (2020). Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clinical Rheumatology, 39, 2085–2094.
4. Sarzi-Puttini P, G. V. (2020). COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol, 38(2):337–342.
7. Xu Z, S. L. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 8(4), 420-422.
10. Bhaskar S, Sharma D, Walker AH, McDonald M, Huasen B, Haridas A, et al. Acute neurological care in the COVID-19 era: the pandemic health system REsilience PROGRAM (REPROGRAM) consortium pathway. Front Neurol. (2020) 11:579. doi: 10.3389/fneur.2020.00579.
11. Bhaskar S, Bradley S, Israeli-Korn S, Menon B, Chattu VK, Thomas P, et al. Chronic neurology in COVID-19 era: clinical considerations and recommendations from the REPROGRAM Consortium. Front Neurol. (2020) 11:664. doi: 10.3389/fneur.2020.00664.
12. Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, Reyes-Bueno JA, Ciano Petersen N, Aguilar-Castillo MJ, et al. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurología. (2020) 35:245–51. doi: 10.1016/j.nrleng.2020.04.002.